Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VXCO-102 EBV Vaccine in Healthy Young Adults
NCT07557602Phase 1Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2026
- Primary completion
- Feb 2028
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised trial of VXCO-102 in Epstein-Barr virus infection (4 arms), sponsored by Eli Lilly and Company. Primary endpoints: Number of Participants with Solicited Local and Systemic Reactions, Number of Participants with Unsolicited Adverse Events and 1 more. Started Nov 2026; status: recruiting.
02
Drugs
VXCO-102
03
Conditions
Epstein-Barr virus infection
Beyond the preview
Go deeper on NCT07557602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07557602.